By Fineline Cube 
AbbVie (NYSE: ABBV) announced on June 26, 2026, that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. This marks a significant expansion of the IL-23 inhibitor into the pediatric population.
Regulatory Expansion Timeline
| Indication | FDA Approval | EMA Approval | Patient Population |
|---|---|---|---|
| Plaque Psoriasis (Adult) | Approved | Approved | Adults with moderate-to-severe disease |
| Psoriatic Arthritis | Approved | Approved | Adult patients |
| Crohn’s Disease | Approved | Approved | Adult patients |
| Ulcerative Colitis | Approved | Approved | Adult patients |
| Pediatric Plaque Psoriasis | Jun 2026 | Pending | Children ≥6 years |
Drug Mechanism & Scientific Profile
- Molecule: Risankizumab (SKYRIZI)
- Target: Interleukin-23 (IL-23) cytokine
- Mechanism: Selective binding to p19 subunit, blocking IL-23 activity
- Therapeutic Rationale: IL-23 is a key cytokine involved in inflammatory processes linked to chronic immune-mediated diseases
- Class Differentiation: Highly selective p19 inhibition versus broader cytokine targeting approaches
Clinical Evidence – Phase 3 OptIMMize Program
| Trial Identifier | Population | Primary Endpoint | Safety Profile |
|---|---|---|---|
| NCT04435600 | Pediatric psoriasis | Efficacy endpoints met | Consistent with adult profile |
| NCT04862286 | Pediatric psoriasis | Efficacy endpoints met | Consistent with adult profile |
The Phase 3 OptIMMize clinical trial program demonstrated efficacy in pediatric patients, with a safety profile consistent with the established adult safety data, supporting the regulatory approval for this younger population.
Market Impact & Commercial Strategy
- Addressable Population Expansion: Adds approximately 200,000+ pediatric patients in the U.S. to SKYRIZI’s addressable market
- Competitive Positioning: First IL-23 inhibitor approved for pediatric psoriasis aged 6+, creating differentiation from TNF inhibitors and other biologics
- Revenue Growth Catalyst: Pediatric indication expected to contribute incremental revenue starting 2027
- Franchise Strengthening: Reinforces SKYRIZI as AbbVie’s cornerstone immunology asset alongside HUMIRA biosimilar competition
- Global Rollout: U.S. approval likely to support regulatory submissions in other major markets including EU and Japan
This pediatric approval represents AbbVie’s continued investment in expanding its immunology franchise and addresses a significant unmet need in pediatric dermatology, where treatment options have historically been limited.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to market adoption, competitive dynamics, and healthcare policy changes.-Fineline Info & Tech